정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 625 | Completed | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects | SARS-CoV-2 | Biological: BNT162b1 Other: Placebo |
Phase 1 | BioNTech SE, Shanghai Fosun Pharmaceutical Development Co, Ltd. | INDUSTRY | 144 | All | 18 Years ~ 85 Years | Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China |
| 624 | Active, not recruiting | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population | SARS-CoV-2 | Biological: BNT162b2 Other: Placebo |
Phase 2 | BioNTech SE, Shanghai Fosun Pharmaceutical Development Co, Ltd. | INDUSTRY | 950 | All | 18 Years ~ 85 Years | Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China |
| 623 | Not yet recruiting | Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine | Covid19 | Biological: SARS-CoV-2 Protein Subunit Recombinant Vaccine Biological: SARS-CoV-2 Inactivated Vaccine |
Phase 2 | PT Bio Farma, Fakultas Kedokteran Universitas Indonesia, National Institute of Health Research and Development, Ministry of Health Republic of Indonesia | INDUSTRY | 780 | All | 18 Years | Fakultas Kedokteran Universitas Indonesia, Jakarta, Greater Jakarta, Indonesia |
| 622 | Completed | Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19 | Covid19 | Biological: MVA-SARS-2-S vaccinations (days 0 & 28) Biological: Comirnaty |
Phase 1 | Universitatsklinikum Hamburg-Eppendorf, German Center for Infection Research, Philipps University Marburg Medical Center, Ludwig-Maximilians - University of Munich | OTHER | 30 | All | 18 Years ~ 55 Years | CTC North GmbH & Co KG at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany |
| 621 | Recruiting | Safety and Immunogenicity of the Inactivated Kocak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo | COVID-19 Vaccine | Biological: Kocak-19 Inaktif Adjuvanlı COVID-19 Vaccine 4 μg/0.5 ml Vaccine Biological: Kocak-19 Inaktif Adjuvanlı COVID-19 Vaccine 6 μg/0.5 ml Vaccine Biological: Placebo |
Phase 1 | Kocak Farma | INDUSTRY | 38 | All | 18 Years ~ 55 Years | Yeditepe AR-GE ve Analiz Merkezi ?yi Klinik Uygulamaları Merkezi (Center for GCP), Istanbul, Turkey |
| 620 | Recruiting | Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC | COVID-19 Vaccine | Biological: ERUCOV-VAC Other: Placebo Vaccine |
Phase 1 | Health Institutes of Turkey, TC Erciyes University | OTHER_GOV | 44 | All | 18 Years ~ 55 Years | Erciyes University Hakan Cetinsaya Iyi Klinik Uygulama ve Arastirma Merkezi, IKUM (Center for GCP), Kayseri, Turkey |
| 619 | Not yet recruiting | Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19) | Covid19 | Biological: AZD1222 Biological: rAd26-S |
Phase 2 | R-Pharm, AstraZeneca | INDUSTRY | 100 | All | 18 Years ~ 100 Years |